




CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:

September 16, 2005  
Date

  
Steven L. Highlander

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Fernando Dangond et al.

Serial No.: 10/670,766

Filed: September 25, 2003

For: TREATMENT OF PATIENTS WITH  
MULTIPLE SCLEROSIS BASED ON  
GENE EXPRESSION CHANGES IN  
CENTRAL NERVOUS SYSTEM  
TISSUES

Group Art Unit: 1632

Examiner: Joanne Hama

Atty. Dkt. No.: PART:005US/SLH

**RESPONSE TO RESTRICTION REQUIREMENT DATED APRIL 19, 2005 AND  
REQUEST FOR EXTENSION OF TIME**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Restriction Requirement dated April 19, 2005 for which the date for response was May 19, 2005.

A request for a four-month extension of time to respond is included herewith along with the required fee. This four-month extension will bring the due date to September 19, 2005, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under

37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/PART:005US/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 25-46, 49 and 52-56, *i.e.*, the Group II claims. Further Applicants elect the gene guanylate kinase (GUK1).